A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell LymphomaHepatosplenic T-cell LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaAggressive NK Cell LeukemiaSystemic EBV1 T-cell Lymphoma, if CD8 PositiveHydroa Vacciniforme-Like Lymphoproliferative DisorderExtranodal NK/T Cell Lymphoma, Nasal TypeEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaCytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Interventions
DRUG

DR-01

DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Trial Locations (36)

3121

RECRUITING

Dren Investigational Site, Richmond

3168

RECRUITING

Dren Investigational Site, Clayton

6009

RECRUITING

Dren Investigational Site, Nedlands

10021

RECRUITING

Dren Investigational Site 1, New York

10032

NOT_YET_RECRUITING

Dren Investigational Site 2, New York

10117

RECRUITING

Dren Investigational Site, Berlin

15213

RECRUITING

Dren Investigational Site 2, Pittsburgh

22031

RECRUITING

Dren Investigational Site, Fairfax

22903

RECRUITING

Dren Investigational Site, Charlottesville

31059

RECRUITING

Dren Investigational Site, Toulouse

33612

RECRUITING

Dren Investigational Site, Tampa

35000

RECRUITING

Dren Investigational Site, Rennes

35233

RECRUITING

Dren Investigational Site, Birmingham

37007

RECRUITING

Dren Investigational Site, Salamanca

40126

RECRUITING

Dren Investigational Site, Bologna

43210

RECRUITING

Dren Investigational Site, Columbus

50937

NOT_YET_RECRUITING

Dren Investigational Site, Cologne

69310

RECRUITING

Dren Investigational Site, Pierre-Bénite

77030

RECRUITING

Dren Investigational Site, Houston

91010

RECRUITING

Dren Investigational Site, Duarte

94063

RECRUITING

Dren Investigational Site, Redwood City

98109

RECRUITING

Dren Investigational Site, Seattle

06519

RECRUITING

Dren Investigational Site, New Haven

02114

NOT_YET_RECRUITING

Dren Investigational Site, Boston

04103

RECRUITING

Dren Investigational Site, Leipzig

Unknown

RECRUITING

Dren Investigational Site 1, Hong Kong

RECRUITING

Dren Investigational Site 2, Hong Kong

RECRUITING

Dren Investigational Site 1, Busan

RECRUITING

Dren Investigational Site 2, Busan

RECRUITING

Dren Investigational Site, Goyang-si

RECRUITING

Dren Investigational Site 1, Seoul

RECRUITING

Dren Investigational Site 2, Seoul

RECRUITING

Dren Investigational Site 3, Seoul

RECRUITING

Dren Investigational Site, Tainan City

RECRUITING

Dren Investigational Site, Taipei

08035

RECRUITING

Dren Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dren Bio

INDUSTRY

NCT05475925 - A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Biotech Hunter | Biotech Hunter